Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use.

Samkoe KS, Gunn JR, Marra K, Hull SM, Moodie KL, Feldwisch J, Strong TV, Draney DR, Hoopes PJ, Roberts DW, Paulsen K, Pogue BW.

Mol Imaging Biol. 2017 Aug;19(4):512-521. doi: 10.1007/s11307-016-1033-y.

PMID:
27909986
2.

Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.

de Souza AL, Marra K, Gunn J, Samkoe KS, Kanick SC, Davis SC, Chapman MS, Maytin EV, Hasan T, Pogue BW.

Br J Cancer. 2016 Sep 27;115(7):805-13. doi: 10.1038/bjc.2016.267. Epub 2016 Aug 30.

3.

Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions.

de Souza AL, Marra K, Gunn J, Samkoe KS, Hoopes PJ, Feldwisch J, Paulsen KD, Pogue BW.

Mol Imaging Biol. 2017 Feb;19(1):41-48. doi: 10.1007/s11307-016-0980-7.

4.

Image-derived arterial input function for quantitative fluorescence imaging of receptor-drug binding in vivo.

Elliott JT, Samkoe KS, Davis SC, Gunn JR, Paulsen KD, Roberts DW, Pogue BW.

J Biophotonics. 2016 Mar;9(3):282-95. doi: 10.1002/jbio.201500162. Epub 2015 Sep 9.

5.

Perfusion CT estimates photosensitizer uptake and biodistribution in a rabbit orthotopic pancreatic cancer model: a pilot study.

Elliott JT, Samkoe KS, Gunn JR, Stewart EE, Gardner TB, Tichauer KM, Lee TY, Hoopes PJ, Pereira SP, Hasan T, Pogue BW.

Acad Radiol. 2015 May;22(5):572-9. doi: 10.1016/j.acra.2014.12.014. Epub 2015 Feb 14.

6.

Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging.

Tichauer KM, Samkoe KS, Gunn JR, Kanick SC, Hoopes PJ, Barth RJ, Kaufman PA, Hasan T, Pogue BW.

Nat Med. 2014 Nov;20(11):1348-53. doi: 10.1038/nm.3732. Epub 2014 Oct 26.

7.

Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach.

Samkoe KS, Tichauer KM, Gunn JR, Wells WA, Hasan T, Pogue BW.

Cancer Res. 2014 Dec 15;74(24):7465-74. doi: 10.1158/0008-5472.CAN-14-0141. Epub 2014 Oct 24.

8.

Accounting for pharmacokinetic differences in dual-tracer receptor density imaging.

Tichauer KM, Diop M, Elliott JT, Samkoe KS, Hasan T, St Lawrence K, Pogue BW.

Phys Med Biol. 2014 May 21;59(10):2341-51. doi: 10.1088/0031-9155/59/10/2341. Epub 2014 Apr 17.

9.

Modulation of hypoxia by magnetic nanoparticle hyperthermia to augment therapeutic index.

Chen EY, Samkoe KS, Hodge S, Tai K, Hou H, Petryk AA, Strawbridge R, Hoopes PJ, Khan N.

Adv Exp Med Biol. 2014;812:87-95. doi: 10.1007/978-1-4939-0620-8_12.

PMID:
24729219
10.

Direct characterization of arterial input functions by fluorescence imaging of exposed carotid artery to facilitate kinetic analysis.

Elliott JT, Tichauer KM, Samkoe KS, Gunn JR, Sexton KJ, Pogue BW.

Mol Imaging Biol. 2014 Aug;16(4):488-94. doi: 10.1007/s11307-013-0715-y.

11.

Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging.

Tichauer KM, Deharvengt SJ, Samkoe KS, Gunn JR, Bosenberg MW, Turk MJ, Hasan T, Stan RV, Pogue BW.

Mol Imaging Biol. 2014 Jun;16(3):372-82. doi: 10.1007/s11307-013-0692-1. Epub 2013 Nov 12.

12.

Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo.

Davis SC, Samkoe KS, Tichauer KM, Sexton KJ, Gunn JR, Deharvengt SJ, Hasan T, Pogue BW.

Proc Natl Acad Sci U S A. 2013 May 28;110(22):9025-30. doi: 10.1073/pnas.1213490110. Epub 2013 May 13.

13.

Dual-tracer background subtraction approach for fluorescent molecular tomography.

Tichauer KM, Holt RW, El-Ghussein F, Davis SC, Samkoe KS, Gunn JR, Leblond F, Pogue BW.

J Biomed Opt. 2013 Jan;18(1):16003. doi: 10.1117/1.JBO.18.1.016003.

14.

Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors.

Tichauer KM, Samkoe KS, Klubben WS, Hasan T, Pogue BW.

Phys Med Biol. 2012 Oct 21;57(20):6647-59. doi: 10.1088/0031-9155/57/20/6647. Epub 2012 Oct 1.

15.

Computed tomography-guided time-domain diffuse fluorescence tomography in small animals for localization of cancer biomarkers.

Tichauer KM, Holt RW, Samkoe KS, El-Ghussein F, Gunn JR, Jermyn M, Dehghani H, Leblond F, Pogue BW.

J Vis Exp. 2012 Jul 17;(65):e4050. doi: 10.3791/4050.

16.

Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging.

Tichauer KM, Samkoe KS, Sexton KJ, Gunn JR, Hasan T, Pogue BW.

J Biomed Opt. 2012 Jun;17(6):066001. doi: 10.1117/1.JBO.17.6.066001.

17.

In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging.

Tichauer KM, Samkoe KS, Sexton KJ, Hextrum SK, Yang HH, Klubben WS, Gunn JR, Hasan T, Pogue BW.

Mol Imaging Biol. 2012 Oct;14(5):584-92. doi: 10.1007/s11307-011-0534-y.

18.

Protoporphyrin IX fluorescence contrast in invasive glioblastomas is linearly correlated with Gd enhanced magnetic resonance image contrast but has higher diagnostic accuracy.

Samkoe KS, Gibbs-Strauss SL, Yang HH, Khan Hekmatyar S, Jack Hoopes P, O'Hara JA, Kauppinen RA, Pogue BW.

J Biomed Opt. 2011 Sep;16(9):096008. doi: 10.1117/1.3622754.

19.

High vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas.

Samkoe KS, Sexton K, Tichauer KM, Hextrum SK, Pardesi O, Davis SC, O'Hara JA, Hoopes PJ, Hasan T, Pogue BW.

Mol Imaging Biol. 2012 Aug;14(4):472-9. doi: 10.1007/s11307-011-0503-5.

20.

Comparing implementations of magnetic-resonance-guided fluorescence molecular tomography for diagnostic classification of brain tumors.

Davis SC, Samkoe KS, O'Hara JA, Gibbs-Strauss SL, Paulsen KD, Pogue BW.

J Biomed Opt. 2010 Sep-Oct;15(5):051602. doi: 10.1117/1.3483902.

Supplemental Content

Loading ...
Support Center